Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer

Erlotinib is active in patients with lung cancer; especially those who demonstrate a mutation in exons 18-21 in the epidermal growth factor receptor (EGFR) gene. Patients with lung cancer and brain metastases have poor prognosis as systemic chemotherapy is ineffective in treating the central nervous...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Siavash Jabbari, Michael Pins, Kimberly Kruczek, Chadi Nabhan
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2011
Materias:	brain metastasis erlotinib lung cancer tarceva Medicine R
Acceso en línea:	https://doaj.org/article/fc728a39eb094ea3938b165e4526d5b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc728a39eb094ea3938b165e4526d5b2
record_format	dspace
spelling	oai:doaj.org-article:fc728a39eb094ea3938b165e4526d5b22021-12-02T16:24:51ZErlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer2231-07702249-446410.4103/2231-0770.90916https://doaj.org/article/fc728a39eb094ea3938b165e4526d5b22011-10-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/2231-0770.90916https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Erlotinib is active in patients with lung cancer; especially those who demonstrate a mutation in exons 18-21 in the epidermal growth factor receptor (EGFR) gene. Patients with lung cancer and brain metastases have poor prognosis as systemic chemotherapy is ineffective in treating the central nervous system (CNS) metastases due to its inability to cross the blood brain barrier. Herein, we report a case of a 61 year old female who presented with stage IV adenocarcinoma of the lung with bilateral cerebral and cerebellar CNS involvement. The patient′s tumor harbored a mutation in exon 19 in the EGFR gene. Treatment with erlotinib was started as soon as the molecular studies were available with remarkable and complete radiographic response in the CNS disease, and complete resolution of the previously detected metastases. The patient did not receive any other CNS intervention and radiation was not given due to the lack of CNS symptoms.Siavash JabbariMichael PinsKimberly KruczekChadi NabhanThieme Medical and Scientific Publishers Pvt. Ltd.articlebrain metastasiserlotiniblung cancertarcevaMedicineRENAvicenna Journal of Medicine, Vol 01, Iss 02, Pp 52-54 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain metastasis erlotinib lung cancer tarceva Medicine R
spellingShingle	brain metastasis erlotinib lung cancer tarceva Medicine R Siavash Jabbari Michael Pins Kimberly Kruczek Chadi Nabhan Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
description	Erlotinib is active in patients with lung cancer; especially those who demonstrate a mutation in exons 18-21 in the epidermal growth factor receptor (EGFR) gene. Patients with lung cancer and brain metastases have poor prognosis as systemic chemotherapy is ineffective in treating the central nervous system (CNS) metastases due to its inability to cross the blood brain barrier. Herein, we report a case of a 61 year old female who presented with stage IV adenocarcinoma of the lung with bilateral cerebral and cerebellar CNS involvement. The patient′s tumor harbored a mutation in exon 19 in the EGFR gene. Treatment with erlotinib was started as soon as the molecular studies were available with remarkable and complete radiographic response in the CNS disease, and complete resolution of the previously detected metastases. The patient did not receive any other CNS intervention and radiation was not given due to the lack of CNS symptoms.
format	article
author	Siavash Jabbari Michael Pins Kimberly Kruczek Chadi Nabhan
author_facet	Siavash Jabbari Michael Pins Kimberly Kruczek Chadi Nabhan
author_sort	Siavash Jabbari
title	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
title_short	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
title_full	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
title_fullStr	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
title_full_unstemmed	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
title_sort	erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2011
url	https://doaj.org/article/fc728a39eb094ea3938b165e4526d5b2
work_keys_str_mv	AT siavashjabbari erlotiniberadicatesbrainmetastasesfromepidermalgrowthfactorreceptormutantnonsmallcelllungcancer AT michaelpins erlotiniberadicatesbrainmetastasesfromepidermalgrowthfactorreceptormutantnonsmallcelllungcancer AT kimberlykruczek erlotiniberadicatesbrainmetastasesfromepidermalgrowthfactorreceptormutantnonsmallcelllungcancer AT chadinabhan erlotiniberadicatesbrainmetastasesfromepidermalgrowthfactorreceptormutantnonsmallcelllungcancer
_version_	1718384149982609408

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer

Ejemplares similares